Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in the Netherlands / NCT05654675
Recruiting Observational

Evaluation of the Use of the FUR to Quantify Tumor Glucose Consumption in Oncologic PET

NCT05654675 · tracked via the Priya Life Science Netherlands tracker
Sponsor
Academisch Ziekenhuis Maastricht
Phase
Observational
Started
2024-01-15
Last updated
2025-01-29

Condition(s) studied

Lung CancerLymphoma

Investigational drug(s) / intervention(s)

FDG PET/CT

FDG PET/CT: Besides the standard care FDG PET/CT examination, subjects receive a dynamic whole body PET/CT examination.

Study summary

The goal of this study is to evaluate the use of new method to quantify the amount of sugar a tumor consumes using PET/CT. The main questions it aims to answer are:

* Is the new quantification method superior with respect to the method currently used in the clinic?
* Does the new quantification method provide accurate assessment of the sugar consumption of tumours?

Participants who will undergo a standard care FDG PET/CT scan will in additional receive a dynamic PET/CT scan prior to the standard care scan. In addition blood samples will be drawn at three time points during the examination.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who receive an 18F FDG PET/CT scan as part of standard care * Be competent and be 18 years of age or older Exclusion Criteria: * Diabetes (fasted blood glucose \> 7 mmol/L) * Not fasted \> 4 hours * Physical exercise within 24 hours * Earlier treatment for carcinoma with radio/chemo-therapy * Active inflammation (fever \> 38 degrees, CRP \> 5) * Any condition or medical indication (such as claustrophobia) that indicates that the patient will not be able to lie still for the duration of the dynamic PET/CT examination * Pregnant or breast feeding

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Academisch ziekenhuis Maastricht Maastricht Limburg Recruiting

More Academisch Ziekenhuis Maastricht trials in the Netherlands

Patient Recorded Indexing Measurements Recruiting
Southeast Netherlands Advanced Metastatic Breast Cancer Registry Recruiting

Other trials for the same condition

Prospective Data Collection Initiative on Thoracic Malignancies Recruiting
Bronchoscopic Microwave Ablation of Lung Tissue in Surgical Candidates Recruiting
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma Active, not recruiting
Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation Recruiting
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05654675 on ClinicalTrials.gov ↗ ← All trials in the Netherlands